Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

Pharmacokinetic analysis revealed sustained activity at 15 days, a finding corroborated by imaging that demonstrated prolonged tumor retention of the therapeutic agent. Importantly, researchers found ...

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...